| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e53ddadc8822457d5979471ddd1d8ab8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1388b879bde742457c7d1ff79751986
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7826f563f00029584ba60a4ed3f7efa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e8b80b025e743560efe1c9eb581e234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bebded06134c2e0e76ce0b8740f64588
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b576a6c78dbe11b1baad7f245c89b0fe |
| publicationDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190069954-A |
| titleOfInvention |
Sustained-release preparations comprising bepotastine or pharmaceutically acceptable salt thereof |
| abstract |
The present invention relates to a pharmaceutical composition comprising bepotastine or a pharmaceutically acceptable salt thereof; Water-soluble diluent; Sustained release carrier; And magnesium metasilicate aluminate. Although the sustained-release preparation of the present invention was applied to the above-mentioned drug delivery and sustained-release technology without increasing the size, the usage was reduced from twice a day to one time per day, but the same bioavailability as that of the control drug, Thereby improving the convenience of taking a patient, and can be useful for the treatment of allergic rhinitis or pruritus. |
| priorityDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |